Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Salestools Logo

Salestools

Der #1 KI-Agent für Vertriebsteams und Go-to-Market-Teams. Verkaufen Sie mehr, schneller, mit weniger Aufwand.

Produkt

  • KI-Vertriebsagenten
  • Intent-Daten
  • Technologiedaten
  • Besucher-Tracking
  • Co-Pilot
  • Social Selling

Lösungen

  • Kundenservice
  • E-Commerce
  • SaaS
  • Enterprise
  • Kleinunternehmen

Ressourcen

  • Der Report
  • Dokumentation
  • API-Referenz
  • Hilfecenter
  • Blog
  • Fallstudien
  • Webinare

Unternehmen

  • Über uns
  • Karriere
  • Presse
  • Kontakt
  • Partner

Unsere Standorte

  • New York, HQ
  • Bukarest, KI-Forschungslabor
  • Zug, Schweiz

© 2025 Salestools. Alle Rechte vorbehalten.

Datenbedingungen & SicherheitDatenschutzerklärungNutzungsbedingungen
Alle Systeme betriebsbereit
Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Back to The Report
Fundraising

Tango Therapeutics

Tango Therapeutics Raises $165M in Series B

2017
Founded
120+
Employees
100 Binney Street, Cambridge, MA 02142
Updated February 12, 2024
2 min read

Quick Facts

Tango Therapeutics Raises $165M in Series B


Tango Therapeutics has successfully raised $165M in a Series B at a $600M valuation led by Third Rock Ventures, BVF Partners, Boxer Capital, Casdin Capital.


Company Overview


Tango Therapeutics is a Biotech company headquartered in 100 Binney Street, Cambridge, MA 02142, founded in 2017 with 120+ employees.


Cancer therapeutics discovering synthetic lethal drug targets


Fundraising Details


  • Amount Raised: $165M
  • Round Type: Series B
  • Valuation: $600M
  • Date: 2024-02-12
  • Investors: Third Rock Ventures, BVF Partners, Boxer Capital, Casdin Capital

About Tango Therapeutics


Cancer therapeutics discovering synthetic lethal drug targets The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 100 Binney Street, Cambridge, MA 02142
  • Founded: 2017
  • Team Size: 120+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in Tango Therapeutics's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Tango Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $600M valuation marks an important milestone for Tango Therapeutics, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, Tango Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-02-12. For more information about Tango Therapeutics, visit their headquarters at 100 Binney Street, Cambridge, MA 02142.

Topics

Fundraising(2912)Series B(293)BiotechTango Therapeutics

About the Author

Fundraising News Team
Fundraising News Team
Tracking the latest funding rounds and investment news

Related Company Reports

Fundraising
Harvey AI

Harvey AI Raises $160 million in Series F

Harvey AI, a AI Software company based in San Francisco CA, has raised $160 million in Series F at a $8 billion valuation led by Andreessen Horowitz.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•160 million
Fundraising
7AI

7AI Raises $130 million in Series A

7AI, a Cybersecurity company based in Boston MA, has raised $130 million in Series A at a $700 million valuation led by Index Ventures.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•130 million
Fundraising
TRIANA Biomedicines

TRIANA Biomedicines Raises $120 million in Series B

TRIANA Biomedicines, a Biotechnology company based in Lexington MA, has raised $120 million in Series B at a Undisclosed led by Ascenta Capital.

Market Intelligence Team
Market Intelligence Team
Dec 3, 2025
0 min read•120 million